Post-earnings recap
Reported
Thu, Apr 27, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's earnings report showed a slight miss on EPS, which may raise some concerns among investors. However, the stock reacted positively, gaining 0.81%, likely due to management's focus on innovation and long-term growth strategies. The lack of revenue data and guidance leaves some uncertainty for future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.29 | N/A | -4.55% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism about future prospects. They emphasized their commitment to innovation and growth.
Management highlighted ongoing investments in innovation.
They expressed confidence in long-term growth despite current challenges.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—